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The calpain-10 gene (CAPN10) on chromosome 2q37.3 was the ﬁrst candidate gene for type 2 diabetes (T2D)
identiﬁed through a genomewide screen and positional cloning. One polymorphism (UCSNP-43: GrA) and a
speciﬁc haplotype combination deﬁned by three polymorphisms (UCSNP-43, -19, and -63) were linked to an
increased risk of T2D in several populations. To quantitatively assess the collective evidence for the effects of
CAPN10 on risk of T2D, we conducted a meta-analysis of both population-based and family-based association
studies. We retrieved data from the MEDLINE, PubMed, and Online Mendelian Inheritance in Man databases, as
well as from other relevant reports and abstracts published up to July 2003. From a total of 26 studies with primary
data (21 population-based studies: 5,013 cases and 5,876 controls; 5 family-based studies: 487 parent-offspring
trios), we developed a summary database that contains variables of study design, study population/ethnicity, speciﬁc
polymorphisms and haplotype combinations in CAPN10, and diabetes-related metabolic phenotypes. For popu-
lation-based studies, we used both ﬁxed-effects and random-effects models to calculate the pooled odds ratio (OR)
and 95% conﬁdence interval (CI) for the associations of CAPN10 genotypes with the risk of T2D.We also calculated
weighted mean differences for the associations between CAPN10 and diabetes-related quantitative traits. Under
either an additive or a dominant effect model, we found no statistically signiﬁcant relation between CAPN10
genotypes in the UCSNP-43 locus and T2D risk. However, under a recessive model, individuals homozygous for
the common G allele had a statistically signiﬁcant 19% higher risk of T2D than carriers of the A allele (OR 1.19;
95% CI 1.07–1.33). The association between the 112/121 haplotype combination and T2D risk appeared to be
overestimated by several initial small studies with positive ﬁndings (OR 1.38; 95% CI 1.04–1.84). After we removed
these initial studies, this association became nonsigniﬁcant (OR 1.11; 95% CI 0.91–1.35). Moreover, we found no
evidence for the associations between the UCSNP-43 G/G genotype and the 112/121 haplotype combination and
metabolic phenotypes. Our meta-analysis of family-based studies showed only an overtransmission of the rare allele
C in UCSNP-44 from heterozygous parents to their affected offspring with T2D. Our analysis indicates that
inadequate statistical power, racial/ethnic differences in frequencies of alleles, haplotypes and haplotype combi-
nations, potential gene-gene or gene-environment interactions, publication bias, and multiple hypothesis testing
may contribute to the signiﬁcant heterogeneity in previous studies of CAPN10 and T2D. Our ﬁndings also suggest
that both large-scale, well-designed association studies and functional studies are warranted to either reliably conﬁrm
or conclusively refute the initial hypothesis regarding the role of CAPN10 in T2D risk.
Introduction
As a complex metabolic disease, type 2 diabetes mellitus
(T2D [MIM 125853]) is characterized by hyperglycemia
and dyslipidemia and often leads to serious micro- and
macrovascular complications, including cardiovascular
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disease. Although insulin resistance and progressive pan-
creatic b-cell dysfunction have been established as the
two fundamental features in the pathogenesis of T2D
(Kahn 1994), the speciﬁc molecular defects affecting in-
sulin sensitivity and/or b-cell function remain largely un-
deﬁned. The high prevalence of this disease in certain
racial/ethnic groups (Lillioja et al. 1993) and the high
concordance in MZ twin pairs (63%–90%) (Newman
et al. 1987) suggest that susceptibility to T2D is highly
heritable. Linkage analyses have identiﬁed several spe-
ciﬁc gene loci in a handful of families with diabetes that
segregates as an autosomal dominant trait, termed “ma-
turity-onset diabetes of the young” (MODY-1, -2, -3,
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-4, -5, and -6) (Florez et al. 2003). However, much re-
mains unknown about the genetic determinants of the
common (195%) late-onset form of T2D.
For the common form of T2D in the general popu-
lation, the calpain-10 (CAPN10 [MIM 605286]) gene
is the ﬁrst T2D candidate gene identiﬁed through ge-
nomewide linkage and positional cloning (Horikawa et
al. 2000). CAPN10, located on chromosome 2q37.3,
comprises 15 exons spanning 31 kb of genomic se-
quence that encodes a 672-amino-acid intracellular pro-
tease. Calpain-10 is primarily expressed in liver, skeletal
muscle, and pancreatic islets and is one of the nonly-
sosomal cysteine proteases essential for calcium-regu-
lated intracellular signaling (Goll et al. 2003).
Horikawa et al. (2000) ﬁrst reported that homozy-
gosity of the G allele in UCSNP-43 and a “high risk”
haplotype combination (multilocus genotype) deﬁned
by the UCSNP-43 (MIM 605286.0001), -19 (tworthree
repeats of a 32-bp sequence in intron 6) (MIM
605286.0002), and -63 (CrT in intron 13) (MIM
605286.0003) polymorphisms were associated with a
two- to threefold increased risk of T2D in a sample of
Mexican Americans and in two samples of European
populations. However, results from subsequent popula-
tion-based association studies have been inconsistent;
several studies found only a modest effect of CAPN10
(Schwarz et al. 2001; Cassell et al. 2002; Garant et al.
2002; Orho-Melander et al. 2002), whereas others found
no association between CAPN10 variants and T2D risk
(Baier et al. 2000; Evans et al. 2001; Hegele et al. 2001;
Tsai et al. 2001; Xiang et al. 2001a; Daimon et al. 2002;
Fingerlin et al. 2002; Malecki et al. 2002; Rasmussen et
al. 2002; Sun et al. 2002; Horikawa et al. 2003; Iwasaki
et al. 2003). Many studies showed a trend toward sig-
niﬁcance but lacked sufﬁcient power individually to de-
tect a modest genetic effect (Evans et al. 2001; Tsai et al.
2001; Xiang et al. 2001a; Fingerlin et al. 2002; Malecki
et al. 2002; Rasmussen et al. 2002; Sun et al. 2002).
Likewise, data from family-based studies were sparse and
provided little or no conclusive evidence to either conﬁrm
or refute the initial ﬁndings. To provide a comprehensive
and quantitative assessment of the impact of this gene
on risk of T2D, we conducted a meta-analysis of both
population and family-based studies with available pri-
mary data. To further identify issues that may aid in the
design and analysis of future genetic association studies,
we also explored potential sources of heterogeneity in
these studies.
Methods
Study Selection
Relevant studies were identiﬁed by searching the
MEDLINE, PubMed, and OnlineMendelian Inheritance
in Man (OMIM) databases for all published genetic as-
sociation studies up to July 2003, using the search terms
“calpain-10,” “calpain-10 gene,” “CAPN,” “CAPN
gene,” “CAPN-10,” “CAPN-10 genotype,” “insulin re-
sistance,” “glucose metabolism,” “type 2 diabetes,” and
“diabetes.” Additional studies were retrieved through a
hand search of references from original reports. We also
reviewed abstracts presented at the American Diabetes
Association from 2000 to 2003. All studies on this topic
were considered eligible if they had data on the rela-
tionship between CAPN10 genotypes and diabetes-re-
lated quantitative traits and T2D risk. Only one non–
English language article was identiﬁed and included
(Xiang et al. 2001a).
Two of us (Y.S. and S.L.) independently reviewed each
published paper and extracted relevant information ex-
amining the associations of CAPN10 gene polymor-
phisms or haplotype combinations with risk of T2D or
metabolic phenotypes. Interobserver differences, if any
existed, were reconciled through group discussion. In
general, we included studies that provided estimates of
relative risks (RRs) or odds ratios (ORs) of T2D or data
that permitted estimation of these parameters. When a
study reported results on different subpopulations, we
considered each subpopulation as a separate study in the
meta-analysis.
Of the 28 published articles that were identiﬁed and
abstracted, 6 studies were excluded. These included two
redundant reports of the same population (Xiang et al.
2001b; Stumvoll et al. 2002) and four reports that did
not provide relevant data on the risk estimates (Hoffstedt
et al. 2002a, 2002b; Engelman et al. 2003; Schwarz et
al. 2003). The ﬁnal data set of our meta-analyses in-
cluded 21 independent case-control studies of unrelated
subjects (see table A1 in the appendix), and ﬁve inde-
pendent family-based studies (Evans et al. 2001; Cassell
et al. 2002; Elbein et al. 2002; Orho-Melander et al.
2002; Sun et al. 2002). Data on CAPN10 genotypes and
diabetes-related metabolic traits were also available in
nine studies (Baier et al. 2000; Stumvoll et al. 2001;
Xiang et al. 2001a; Daimon et al. 2002; Garant et al.
2002; Lynn et al. 2002; Orho-Melander et al. 2002;
Rasmussen et al. 2002; Shore et al. 2002).
We developed a database that included the ﬁrst author’s
name, year of publication, study population, sample size,
mean age for cases and controls, mean age at diagnosis,
mean BMI, fasting plasma glucose levels, comparisons of
allele frequencies between cases and controls, genotype
distribution in cases and controls, and the estimates of
RRs or ORs of T2D associated with the CAPN10 ge-
notypes. Two studies that provided adjusted ORs made
adjustment for age and sex (Baier et al. 2000; Garant et
al. 2002). For family-based association studies, we col-
lected all counts for transmission status of the allele ex-
amined (transmitted or not transmitted from a hetero-
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zygous parent to the affected offspringwith T2D) through
use of transmission/disequilibrium testing (TDT).We also
extracted the number of subjects and the means and SDs
of quantitative metabolic phenotypes, including the fol-
lowing: BMI; waist-to-hip ratio (WHR); plasma levels of
high-density lipoprotein (HDL), low-density lipoprotein,
and triglyceride; fasting plasma glucose and insulin levels;
plasma levels of glucose, insulin, and C-peptide at 2 h
after a 75-g oral glucose tolerance test; homeostasismodel
assessment of insulin resistance (HOMA-IR) index; and
early insulin response (EIR).
Statistical Analyses
Population-based association analysis.—We calculat-
ed the ORs and 95% CIs for the associations between
CAPN10 genotypes and risk of T2D, through use of
both the ﬁxed-effects and the random-effects models. To
explore the inheritance model for the effect of UCSNP-
43 polymorphism, we evaluated the following genotype
contrasts: G/G versus G/A and A/A combined (a reces-
sive effect); G/G and G/A combined versus A/A (a dom-
inant effect); G/G versus G/A; G/A versus A/A; and G/
G versus A/A (additive or dose-response effect).
In the ﬁxed-effects model, the summary OR was ob-
tained by averaging the natural logarithms of the ORs
from individual studies, weighted by the inverses of their
variances. When the adjusted ORs were not available
from the article, we used the crude ORs reported or cal-
culated from the raw data. To incorporate both within-
study and between-study variability, we used DerSi-
monian and Laird’s (1986) random-effects model. To
further test the robustness of results obtained from both
ﬁxed-effects and random-effects models, we also applied
the empirical Bayes method in a sensitivity analysis. Em-
pirical Bayes estimates are calculated by shrinking the
study-speciﬁc estimates towards the overall random-ef-
fects estimate by a factor that depends on the relative
magnitude of the estimated within- and between-study
variances (Normand 1999). Formal tests of heterogeneity
were assessed by a x2 statistic.
We also computed the population-attributable risk
(PAR) of UCSNP-43, which indicates the fraction of
T2D cases in the population that can be attributed
to the independent effect of the G/G genotype. PAR
was calculated, on the basis of case-control studies,
as %PARp [b# (OR 1.0)] / [b# (OR 1.0) 1.0]
(Greenland 1998), where b is the prevalence of the G/
G genotype in the source population, and the OR is the
estimated pooled risk of T2D in individuals with the G/
G genotype relative to that of those carrying the A allele.
Family-based association analysis.—For family-based
studies, we calculated a transmission ratio from hetero-
zygous parents in the trio population from each TDT,
which is equivalent to an OR calculated from the
McNemar test. The x2 statistic was used to calculate P
values for the TDT, and 95% CIs were calculated on
the basis of a binomial distribution.
Assessment of publication bias.—We assessed publi-
cation bias through use of Begg’s modiﬁed funnel plots,
in which the OR was plotted on a logarithmic scale
against its SE from each study (Egger et al. 2001). Pub-
lication bias was also assessed by two formal tests: Begg’s
adjusted rank correlation test and Egger’s regression
asymmetry test. The former was used to examine whether
there is signiﬁcant correlation between the effect estimates
and their variances, and the latter uses an inverse-variance
weighted regression of the effect sizes on their precision
(the inverse of SE) to test whether the intercept deviates
signiﬁcantly from 0 (Egger et al. 2001). Meta-analyses,
including tests of publication bias, were performed using
Stata statistical software (version 7.0; Stata Web site).
Sample size estimation.—To evaluate the sufﬁciency
of statistical power in previous studies, we calculated the
necessary sample size to achieve a given power for the
CAPN10-T2D relation in both the population-based
case-control design and the family-based association
study design (TDT) (Gauderman 2002).
Results
Characteristics of Association Studies
Of the 21 studies involving a total of 5,013 cases and
5,876 controls, one-third involved white Europeans,
one-third involved Americans, and one-third involved
Asians (details of characteristics of included studies are
given in the appendix). American populations included
Mexican Americans, Pima Indians, African Americans,
and Samoans. The mean age at diagnosis for affected
individuals ranged from 46 to 56 years. Overall, subjects
with diabetes had higher BMIs and fasting insulin levels
than did control subjects. Five studies also reported in-
dependent family-based studies that examined the trans-
mission of alleles or haplotypes from heterozygous par-
ents to affected offspring in populations that included
Chinese (Sun et al. 2002), Utah whites (Elbein et al.
2002), Finns (Orho-Melander et al. 2002), British/Irish
whites (Evans et al. 2001), and South Indians (Cassell
et al. 2002).
Allele Frequencies of UCSNP-44, -43, -19, -63
Polymorphisms in CAPN10
Table 1 shows signiﬁcant differences in the allele
frequencies of UCSNP-44, -43, -19, and -63 poly-
morphisms across different populations (dbSNP IDs
rs2975760, rs3792267, rs3842570, and rs5030952, re-
spectively [dbSNP Home Page]). In particular, the G al-
lele frequency of UCSNP-43 in controls varied from 0.62
(Pima Indians) to 0.96 (Japanese). However, the allele
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Table 1
Allele Frequencies of UCSNP-44, -43, -19, and -63 Polymorphisms in the CAPN10 Gene Reported in 11 Diverse Populations
STUDY POPULATION
NO. OF
CASES/NO.
OF
CONTROLSa
FREQUENCY OFb
UCSNP-44 (T/C)
T Allele
UCSNP-43 (G/A)
G Allele
UCSNP-19 (del/ins)c
del Allele
UCSNP-63 (C/T)
C Allele
Cases Controls Cases Controls Cases Controls Cases Controls
British/Irish 444/424 .84 .86 .73 .72 NA NA NA NA
Finnd 395/298 .80 .77 .75 .71 .51 .50 .89 .92
German 232/88 NA NA .72 .66 .66 .73 .92 .94
Polish 229/148 NA NA .73 .69 .66 .65 .93 .91
Scandinavian 409/200 NA NA .73 .72 .62 .60 NA NA
African Americans 166/993 NA NA .89 .87 NA NA NA NA
Mexican Americans 233/101 NA NA .80 .75 .42 .43 .77 .77
Samoan 172/96 NA NA .91 .91 .67 .63 .85 .84
Pima Indian 298/677 NA NA .63 .62 NA NA NA NA
Chinesee 297/296 .87 .91 .90 .89 .70 .67 .80 .78
Japanesee 382/866 .88 .90 .96 .96 .62 .63 .74 .72
Total 3,257/4,187 .83 .85 .78 .77 .59 .58 .88 .87
a Total numbers of cases and controls from all studies that provided allele data.
b NA p data not available.
c UCSNP-19 alleles are two repeats of 32-bp sequence and three repeats (or 32-bp deletion/insertion).
d Signiﬁcant differences in allele frequencies between cases and controls are reported for UCSNP-43 in Finnish populations
( and ) (Horikawa et al. 2000; Orho-Melander et al. 2002) and for UCSNP-63 in one Finnish population (P ! .05 Pp .011 P !
) (Horikawa et al. 2000)..05
e Multiple studies for the same study population were combined to form one case and one control group.
frequencies of these four polymorphisms were not sig-
niﬁcantly different between cases and controls. In only
two Finnish populations did T2D cases have a signiﬁ-
cantly higher frequency for the G allele in UCSNP-43
than controls (case vs. control: 0.77 vs. 0.67, ;P ! .05
and 0.77 vs. 0.67, ) (Horikawa et al. 2000;Pp .005
Orho-Melander et al. 2002). The rare allele T in UCSNP-
63 was more frequent in cases than controls in one Finn-
ish population (Horikawa et al. 2000). On the basis of
studies that presented only allele data, we estimated that
the pooled ORs were 0.96 (95% CI 0.80–1.15) for
UCSNP-44 (T carriers vs. C carriers), 0.97 (95% CI
0.88–1.07) for -19 (carriers of two repeats of 32-bp se-
quence vs. carriers of three repeats), and 0.99 (95% CI
0.86–1.15) for -63 (C carriers vs. T carriers).
UCSNP-43 and T2D Risk
Analysis of population-based studies.—Under a reces-
sive model, the G allele appeared to confer a greater risk
for T2D. Speciﬁcally, individuals homozygous for the G
allele had a 19% increased risk of T2D compared with
those with the G/A or A/A genotypes (OR 1.19; 95%
CI 1.07–1.33) (ﬁg. 1A). Under either an additive or a
dominant effect model, however, we found no statisti-
cally signiﬁcant relation between CAPN10 genotypes in
the UCSNP-43 locus and T2D risk (table 2).
Analysis of family-based studies.—In ﬁve family-based
studies with a total of 487 trios in populations of Chi-
nese (Sun et al. 2002), Utah whites (Elbein et al. 2002),
Finns (Orho-Melander et al. 2002), British/Irish whites
(Evans et al. 2001), and South Indians (Cassell et al.
2002), we found no evidence for overtransmission of the
G alleles in UCSNP-43 from heterozygous parents to
diabetic offspring (table 3).
Haplotypes and Other SNPs in CAPN10 and T2D risk
Analysis of population-based studies.—The haplo-
types in CAPN10 were deﬁned from three or four poly-
morphisms spanned across the gene: UCSNP-43 (G/A
within intron 3; allele 1p G and allele 2p A), UCSNP-
19 (two repeats of 32-bp sequence or three repeats of
32-bp sequence within intron 6; allele 1 p two repeats
and allele 2 p three repeats), and UCSNP-63 (C/T
within intron 13; allele 1p C and allele 2p T), without
or with UCSNP-44 (T/C within intron 3; allele 1 p T
and allele 2 p C) (ﬁg. 2) (GenBank). UCSNP-43, -19,
and -63 polymorphisms were used to deﬁne four most
common haplotypes (i.e., 111, 112, 121, and 221).
These polymorphisms plus UCSNP-44 deﬁned ﬁve most
common haplotypes: 1111, 2111, 1121, 1221, and 1112
(ﬁg. 2). It is notable that the -44 and -43 loci are 11 bp
apart but are not in complete linkage disequilibrium
(LD). The common haplotypes span from intron 3 to
intron 13 (a 11.5-kb region) and account for 99% of
all haplotypes observed. However, there were consid-
erable differences in the frequencies of haplotype com-
binations across different populations (table 4). The 112
haplotype was common in Asians but rare in whites,
and the 121 haplotype was quite common in various
populations. The frequencies of the 112/121 haplotype
Figure 1 Pooled estimates of OR of T2D and 95% CI, comparing individuals with the G/G genotype of UCSNP43 versus all carriers of
the A allele (A) and the 112/121 haplotype combination versus all others (B). Black squares indicate the OR in each study, with the size of the
square inversely proportional to its variance, and horizontal lines represent the 95% CIs. The pooled OR and its 95% CI are indicated by the
unshaded diamond. Three studies reported results on different populations: “Horikawa 1, 2, and 3” indicate Mexican-American, German, and
Finnish populations, respectively; “Schwarz 1 and 2” are German and Czech populations, respectively; and “Fingerlin 1 and 2” are two Finnish
populations.
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Table 2
Pooled Estimates of ORs and 95% CIs for the Association between UCSNP-43 Polymorphism
in the CAPN10 Gene and T2D Risk, from Population-Based Association Studies
GENOTYPE
COMPARISON Na
NO. OF
CASES/NO. OF
CONTROLSb
OR (95% CI) UNDER MODEL
P FOR
HETEROGENEITYFixed-Effects Random-Effects
Recessive model:
G/G vs. G/AA/A 11 2,288/3,041 1.19 (1.07–1.33) 1.18 (1.02–1.35) .20
Dominant model:
G/GG/A vs. A/A 6 1,399/2,314 1.09 (.82–1.44) 1.09 (.82–1.44) .71
Additive model:
G/G vs. G/A 7 1,480/2,395 1.13 (.95–1.33) 1.13 (.95–1.33) .95
G/A vs. A/A 6 1,399/2,314 1.03 (.77–1.39) 1.03 (.77–1.39) .71
G/G vs. A/A 6 1,399/2,314 1.14 (.85–1.53) 1.14 (.85–1.53) .72
a Total number of studies with data available.
b Total numbers of cases and controls from all studies that provided genotype data.
combination were extremely diverse, ranging from 0.01
in German populations (Horikawa et al. 2000) to 0.32
in Japanese populations (Horikawa et al. 2003; Iwasaki
et al. 2003). All large ORs 12.00 with wide 95% CIs
were reported by the ﬁrst study in three populations and
by the two smallest studies. Overall, the 112/121 hap-
lotype combination had only a moderately increased risk
of T2D for all studies combined (pooled OR 1.38; 95%
CI 1.04–1.84), with signiﬁcant between-study hetero-
geneity ( ; ) (ﬁg. 1B).2x p 24.1 Pp .0313
Analysis of family-based studies.—In the pooled sam-
ple of 356 informative trios, the overall transmission
ratio was statistically signiﬁcant only for UCSNP-44
(pooled OR 0.66; 95% CI 0.49–0.88; ) (tablePp .004
3). Allele transmission from UCSNP-63 heterozygotes
showed favorable transmission of the common allele
“C,” although only the pooled estimated OR reached
borderline signiﬁcance (pooled OR 1.40; 95% CI 1.00–
1.95; ). In the pooled analysis of TDT for hap-Pp .05
lotypes deﬁned by these three or four polymorphisms,
a preferential transmission of the rare allele “C” in the
UCSNP-44 locus linked with the haplotype 111 was ev-
ident (pooled OR 1.37; 95% CI 1.04–1.80; )Pp .03
(table 3).
CAPN10 and Diabetes-Related Quantitative Traits
Compared with carriers of the A allele, individuals
homozygous for the G allele in the UCSNP-43 locus had
slightly higher systolic blood pressure, but this ﬁnding
was based on very limited data (from three studies) (table
5). In all other metabolic parameters—including BMI;
WHR; plasma levels of lipids; fasting insulin and glucose
levels; and plasma glucose, insulin, and C-peptide levels
in response to a 2-h 75-g oral glucose tolerance test
(OGTT)—there were no statistically signiﬁcant differ-
ences between carriers of the G/G genotype and carriers
of the A allele (table 5), and there were no signiﬁcant
differences in quantitative metabolic parameters be-
tween carriers of the 112/121 haplotype combination
and all others.
Publication Bias and Sensitivity Analyses
Figure 3 shows a funnel plot for the visual assessment
of publication bias. In the absence of publication bias,
one would expect studies of all sizes to be scattered
equally above and below the line representing the pooled
estimate of log OR. The results showed no evidence of
the presence of substantial publication bias for the as-
sociation between the homozygosity of the G allele of
UCSNP-43 and T2D ( for Begg’s test andPp .24
for Egger’s test) (ﬁg. 3A) (Stata Web site). Fur-Pp .28
thermore, our sensitivity analysis using the empirical
Bayes estimation yielded the same results of the pooled
OR of T2D comparing the homozygosity of the G allele
to carriers of the A allele (OR 1.19; 95% CI 1.07–1.33)
as those from both ﬁxed-effects and random-effects
models.
For haplotype comparison, however, the ORs with
large SEs tended to scatter above the horizontal line,
indicating signiﬁcant publication bias in favor of small
studies with positive ﬁndings ( for Begg’s testPp .006
and for Egger’s test) (ﬁg. 3B) (Stata Web site).Pp .001
After excluding the initial results, the pooled OR com-
paring the 112/121 haplotype combination to all others
became nonsigniﬁcant (OR 1.11; 95% CI 0.91–1.35; P
for heterogeneityp .14). If we excluded all results from
the three smallest studies, the pooled ORwas attenuated
toward the null (OR 1.04; 95% CI 0.84–1.27; P for
heterogeneity p .57) (ﬁg. 1B).
Assessment of Statistical Power
To provide an accurate assessment of sufﬁciency of
statistical power in previous studies, we calculated the
sample size required to detect a modest genetic effect
under the assumption of a recessive model. For popu-
lation-based studies, an equal number of 2,188 cases and
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Table 3
Pooled Estimates of Transmission Ratios (from Heterozygous Parents to Their Affected Offspring), for UCSNP-44, -43,
-19, and -63 Polymorphisms and Haplotypes Deﬁned from Them, Based on Family-Based Association Studies (TDT)
CAPN10 VARIANTa Nb
NO. OF ALLELES
TRANSMISSION
RATIO (95% CI)c
P
VALUEd
P FOR
HETEROGENEITYTransmitted
Not
Transmitted
UCSNP:
-44 3 77 117 .66 (.49–.88) .004 .96
-43 5 239 259 .92 (.77–1.10) .37 .57
-19 4 232 261 .89 (.75–1.06) .19 .78
-63 4 84 60 1.40 (1.00–1.95) .05 .80
Haplotype (-43, -19, -63):
111 3 133 129 1.03 (.81–1.32) .80 .22
112 3 31 42 .74 (.50–1.19) .18 .18
121 3 167 191 .87 (.71–1.08) .21 .82
221 3 113 103 1.10 (.84–1.43) .50 .76
Haplotype (-44, -43, -19, -63):
1111 3 91 93 .98 (.73–1.31) .89 .30
2111 3 119 87 1.37 (1.04–1.80) .03 .59
1121 3 166 188 .88 (.72–1.09) .24 .77
1221 3 113 102 1.11 (.85–1.45) .46 .80
1112 3 29 42 .70 (.43–1.13) .15 .12
a Allele designations in polymorphisms: UCSNP-44: allele 1 p T, allele 2 p C; UCSNP 43: allele 1p G, allele 2p A;
UCSNP-19: allele 1 p two repeats of 32-bp sequence, allele 2 p three repeats (or 32 bp deletion/insertion); UCSNP-63:
allele 1 p C, allele 2 p T. The transmission ratios in this table refer to the 1 allele.
b TDT results are from ﬁve independent studies of different populations: British/Irish whites, Finn, Chinese, Utah whites
with northern European ancestry, and South Indian populations. Haplotype data were provided by three studies (Evans et
al. 2001; Cassell et al. 2002; Orho-Melander et al. 2002).
c Transmission ratios and 95% CIs in the TDT were calculated using the McNemar test.
d x2 distributions were used to calculate P values for the pooled OR.
controls would be required to have 80% power to detect
the OR of 1.19 (one-sided test: ) (ﬁg. 4A). There-ap .05
fore, none of the previously published case-control stud-
ies achieved this sample size to conﬁrm the modest (OR
1.19) but important (PAR 10%) genetic association be-
tween UCSNP-43 and T2D risk. For family-based stud-
ies (TDT), the number of parent-offspring trios required
to detect an OR of 1.19 is estimated to be 1,617 for a
power of 80% (one-sided test: ) (ﬁg. 4B). Thus,ap .05
even our pooled TDT analysis with a total of 487 parent-
offspring trios had !40% power to detect this trans-
mission/disequilibrium ratio of 1.19.
Discussion
On the basis of these 21 population-based studies in-
cluding 5,013 T2D cases and 5,876 controls, our meta-
analysis showed a signiﬁcant 19% increased risk of
T2D among individuals with the G/G genotype in the
UCSNP-43 locus relative to all others. However, the as-
sociation between the 112/121 haplotype combination
and T2D risk appeared to be weak and to have signif-
icant between-study heterogeneity. This ﬁnding was not
supported by family-based studies. In addition, we found
no signiﬁcant association between CAPN10 genotypes
and metabolic phenotypes.
Failure to replicate the initial ﬁndings is a major con-
cern in genetic association studies (Altshuler et al. 2000;
Cardon and Bell 2001). False-positive and false-negative
reports from underpowered studies may, in part, explain
the inconsistent replication. In the present study, none of
the previous studies were found to individually achieve
the required statistical power to provide a robust estimate
of the possible modest effect of CAPN10 on T2D risk;
however, our pooled analysis of all available data sug-
gests a modest but signiﬁcant OR of 1.19 for carriers of
the G/G genotype in the UCSNP-43 locus versus carriers
of the A allele. Furthermore, recent evidence showed that
the ﬁrst study tends to overestimate the genetic effects,
which often cannot be replicated in subsequent larger
studies (Ioannidis et al. 2001). Nevertheless, the G/G ge-
notype remained signiﬁcantly associated with T2D even
after removing the ﬁrst study. In addition, our ﬁnding of
a recessive inheritance model for the modest effect of the
UCSNP-43 locus on T2D was compatible with results
from several metabolic studies showing that the G/G ge-
notype was associated with appreciable degrees of phys-
iologic effects, compared with the A/A genotype alone
or with the G/A genotype (Baier et al. 2000; Hoffstedt
et al. 2002b). Taken together, these ﬁndings suggest that
the common G allele in the UCSNP-43 locus may confer
a modest susceptibility to T2D. Because of its high allele
frequency, the modest genetic effect would be translated
into a relatively large PAR. On the basis of the pooled
Song et al.: CAPN10 Gene and Type 2 Diabetes 215
Figure 2 Schematic diagram of the human CAPN10 gene illustrating the location of polymorphisms used to deﬁne haplotypes and one
coding polymorphism. The location of polymorphisms relative to the A of the start codon are 4841 (site 44), 4852 (site 43), 7917 (site 19),
9803 (site 110), and 16378 (site 63). The sequence length for CAPN10 gene is from GenBank (accession number AF158748). Frequencies of
the haplotypes were provided in unrelated control groups.
data, we estimated that the G/G genotype accounts for
10% of total diabetes cases. Nevertheless, it is important
to keep in mind that PAR is meaningful insofar as the
relationship between UCSNP-43 and T2D risk is causal
and that a more accurate estimate of PAR can be esti-
mated only by studies using population-based controls.
In contrast, our analysis of ﬁve family-based studies
provided little support for the association between the
G allele and T2D but revealed a signiﬁcant association
between risk of T2D and the rare allele C in the UCSNP-
44 locus alone or in combination with the 111 haplo-
type (Elbein et al. 2002). However, even this pooled
analysis of family-based studies is not large enough to
provide a reliable estimate of a modest genetic effect.
Additional large-scale studies are needed to conﬁrm this
ﬁnding. To assess a genetic effect under a recessive
model, a future modiﬁed TDT that tests allele trans-
mission from parents to their affected offspring ho-
mozygous for the G allele may be more powerful than
the traditional TDT used in previous studies.
Despite the observed association between the G/G ge-
notype and the risk of T2D, the haplotype that includes
this variant and other adjacent variants did not appear
to increase susceptibility to T2D (Horikawa et al. 2000;
Cox 2001, 2002). In contrast to the two- or threefold
increased risk reported in the original study (Horikawa
et al. 2000), we observed only a moderate effect of the
112/121 haplotype combination on risk of T2D (OR
1.38; 95% CI 1.04–1.84). Furthermore, when we ex-
cluded the initial positive results and/or the other two
smallest studies, the evidence for heterogeneity disap-
peared, and there was no signiﬁcant relation between the
112/121 haplotype combination and T2D risk. It seems
likely that this observed signiﬁcant association was over-
estimated by these underpowered studies. Thus, the hap-
lotype-speciﬁc effects found in the initial study remain
questionable.
Recent empirical data have suggested that LD patterns
in the human genome are characterized by a “haplotype
block” structure, in which a series of high-LD regions is
interspersed with short, discrete segments of very low LD
(which may represent recombination hotspots) (Daly et
al. 2001; Gabriel et al. 2002). Given limited haplotype
diversity within each block, a minimal set of SNPs,
designated as “haplotype-tagging SNPs” (htSNPs), is
thought to be sufﬁcient to capture the LD variation in a
population (Johnson et al. 2001). Therefore, increased
understanding of LD patterns in the genomic sequences
of interest has important implications for the design of
practical haplotype-based association studies. In the orig-
inal study, Horikawa et al. (2000) sequenced a 66-kb
genomic region that encompassesCAPN10 in 10 diabetic
MexicanAmericans and then identiﬁed the high-risk hap-
lotypes on the basis of the evidence from both association
and linkage analysis. Subsequently, most studies have not
determined the haplotype structure of CAPN10 in their
own study samples but, rather, have genotyped the SNPs
(UCSNP-43, -19, -63) originally deﬁned in Mexican
Americans (Horikawa et al. 2000). Such a strategy,
though efﬁcient, may have overlooked the population-
speciﬁc LD pattern in characterizing recombination hot-
spots and choosing htSNPs in the genomic region near
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Table 4
Pooled Estimates of OR and 95% CIs for the Associations between Haplotype Combinations Deﬁned
by UCSNP-43, -19, and -63 Polymorphisms and Risk of T2D
HAPLOTYPE
COMBINATIONa Nb
NO. OF
CASES/NO. OF
CONTROLS
FREQUENCY
RANGEc
OR (95% CI)d UNDER MODEL
P VALUE FOR
HETEROGENEITYFixed Effects Random Effects
111/111 9 184/143 .03–.11 1.16 (.94–1.44) 1.16 (.94–1.44) .89
111/112 10 103/63 .02–.09 1.03 (.79–1.34) 1.03 (.79–1.34) .94
111/121 10 389/257 .11–.24 .96 (.83–1.12) .96 (.83–1.12) .94
112/112 7 36/27 .01–.08 .74 (.46–1.19) .74 (.46–1.19) .91
112/121 14 1,848/1,237 .01–.32 1.22 (1.01–1.47) 1.38 (1.04–1.84) .03
121/121 10 324/178 .06–.33 1.12 (.94–1.34) 1.14 (.90–1.46) .06
221/221 8 121/95 .00–.12 .83 (.66–1.05) .83 (.66–1.05) .83
221/111 9 253/180 .00–.24 .93 (.79–1.08) .93 (.79–1.09) .42
221/112 10 82/55 .01–.14 .95 (.72–1.25) .93 (.62–1.41) .05
221/121 10 311/211 .07–.22 .92 (.78–1.08) .92 (.78–1.08) .52
a Allele designation in haplotype combination: UCSNP 43: allele 1 p G, allele 2 p A; UCSNP-19, allele 1p two
repeats of 32-bp sequence, allele 2 p three repeats; UCSNP-63, allele 1 p C, allele 2 p T.
b Total number of population-based studies included.
c Frequency among control subjects from eight ethnic populations, including Japanese (Horikawa et al. 2003),
Scandinavian (Rasmussen et al. 2002), Polish (Malecki et al. 2002), Samoan (Tsai et al. 2001), Mexican American
(Horikawa et al. 2000), German (Horikawa et al. 2000), and two separate Finnish populations (Horikawa et al. 2000;
Orho-Melander et al. 2002).
d OR and 95% CI of each haplotype combination relative to its corresponding control group (all other haplotype
combinations).
CAPN10. It is thus possible that the CAPN10 variants
chosen for haplotype deﬁnition in previous studies may
not be sufﬁcient and that the haplotypes so deﬁned may
not capture the vast majority of genetic variability of
CAPN10 in diverse populations. Furthermore, all of
these variants used for haplotype deﬁnition are intron-
ic and are very likely to be in LD with other unidenti-
ﬁed functional variants (regulatory or coding polymor-
phisms) within or in the proximity of the CAPN10 locus
(Horikawa et al. 2000; Cox 2002). Only UCSNP-44 has
been observed to be in perfect LD with a coding poly-
morphism in CAPN10 (UCSNP-110: ArG in exon 10
[Thr504Ala], dbSNP ID rs7607759) (Evans et al. 2001;
Schwarz et al. 2001). Several nonsynonymous polymor-
phisms of CAPN10 have been identiﬁed, but most of
them appeared to have relatively rare frequencies (!5%)
(Horikawa et al. 2000; Evans et al. 2001; dbSNP Home
Page; OMIM Web site).
Geographic/ethnic differences in the frequencies of
these known CAPN10 variants, haplotypes, and hap-
lotype combinations are pronounced across multiple
ethnic populations. A recent study of CAPN10 in 561
individuals from 11 populations also showed substan-
tial degrees of diversity in the frequencies of CAPN10
haplotypes between African and non-African popula-
tions (Fullerton et al. 2002). The 121 haplotype was
absent in two African populations, whereas the 112
haplotype appeared to be much more common in these
two African populations (0.59–0.82) than in the non-
African populations (Fullerton et al. 2002). Such genetic
heterogeneity ofCAPN10 in populations of various eth-
nic origins not only affects the power of individual stud-
ies but also indicates different patterns and magnitudes
of LD between variants in this gene among different
ethnic groups (i.e., population-speciﬁc LD). Therefore,
population- or locus-speciﬁc LD patterns may contrib-
ute, at least in part, to inconsistent ﬁndings of previous
studies. Future haplotype-based studies need to care-
fully survey the genomic region in and near CAPN10,
such that the underlying structure of LD for each ethnic
population of interest can be better characterized.
Some essential issues related to genetic association
studies also merit further consideration. First, population
stratiﬁcation may be a concern, especially when data
from diverse populations are included. However, empir-
ical evidence indicates that population stratiﬁcation is
likely to be minimal in well-designed population studies
that match or control for ethnicity (Wacholder et al.
2000; Ardlie et al. 2002; Pankow et al. 2002). Further-
more, bias due to population stratiﬁcation in different
studies appears to be random. Thus, the pooled estimate
from each independent study of ethnically homogeneous
populations is less likely to be biased by the presence of
population stratiﬁcation. Second, differences in control
selection of case-control studies may contribute to het-
erogeneity between studies and may need to be carefully
considered in the design of future association studies.
Epidemiologists have long noted the numerous advan-
tages of the prospective study design over hospital-based
case-control studies in minimizing selection bias or pop-
ulation stratiﬁcation. Of the 21 case-control studies in-
cluded in our analysis, only 1 used population-based con-
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Table 5
Effects of the G/G Genotype of UCSNP-43 and the 112/121 Haplotype Combination on Metabolic Traits in Healthy Nondiabetic Controls
METABOLIC
PARAMETERa
UCSNP-43 G/G VERSUS G/CC/C
112/121 VERSUS ALL OTHER HAPLOTYPE
COMBINATIONS
Nb
Weighted Mean
Difference (95% CI)
P Value for
Heterogeneity Nb
Weighted Mean
Difference (95% CI)
P Value for
Heterogeneity
BMI 7 .05 (.15 to .05) .16 2 .30 (.26 to .86) .14
WHR 7 .05 (.04 to .15) .51 2 .04 (.31 to .39) .70
SBP 3 .14 (.01 to .26) .57 NA NA NA
DBP 3 .11 (.01 to .24) .87 NA NA NA
Total cholesterol 2 .32 (.01 to .63) .24 NA NA NA
HDL-c 2 .07 (.06 to .20) .98 NA NA NA
Triglyceride 2 .09 (.04 to .22) .39 NA NA NA
Fasting insulin 7 .04 (.06 to .14) .41 2 .26 (.62 to .10) .17
Fasting glucose 8 .06 (.03 to .16) .84 3 .06 (.21 to .33) .08
Fasting C-peptide NA NA NA 2 .08 (.28 to .43) .27
2-h post-load glucose 5 .08 (.07 to .22) .46 3 .15 (.48 to .77) .007
2-h post-load insulin 3 .05 (.11 to .21) .56 3 .15 (.13 to .42) .005
2-h post-load C-peptide NA NA NA 2 .15 (.51 to .21) .05
HOMA-IR 4 .06 (.22 to .11) .81 3 .03 (.54 to .60) .02
EIR 1 .04 (.61 to .69) NA 2 .18 (.49 to .12) .49
a SBP p systolic blood pressure; DBP p diastolic blood pressure; OGTT p 75-g oral glucose tolerance test; NA p data not available.
HOMA-IR (homeostasis model assessment of insulin resistance) was calculated as the product of fasting serum insulin and fasting plasma
glucose. EIR p Early insulin response correlated with insulin secretion; determined as the ratio of the 30-min insulin increment to the 30-min
increment in glucose levels following oral glucose loading.
b Total number of studies included.
trols with a prospective study design (Garant et al. 2002).
In that study, the OR of incident diabetes among African
American participants with the G/G genotype compared
with those carrying the A allele was not statistically sig-
niﬁcant (OR 1.21; 95%CI 0.86–1.27), but its magnitude
is similar to our pooled estimated OR. Third, publication
bias may exist, although we have made every attempt to
identify relevant reports. Although we found little evi-
dence of publication bias regarding the association be-
tween UCSNP-43 and T2D, our sensitivity analyses
showed that the excess risk of T2D with the haplotype
combination 112/121 could be explained largely by pub-
lication bias from small studies with positive ﬁndings.
Fourth, possible gene-gene or gene-environmental inter-
actions could lead to the varying genetic effects of
CAPN10 observed in different populations. For example,
previous linkage analysis and a family-based test indicate
an interaction between locus NIDDM1 (MIM 601283)
on chromosome 2q37 and CYP19 (MIM 107910) on
chromosome 15q21.1 in conferring increased suscepti-
bility for T2D (Cox et al. 1999; Engelman et al. 2003).
The UCSNP-19 was found to be associated with reduced
b3-adrenoceptor function in overweight people (BMI 125
kg/m2) but not in lean ones (Hoffstedt et al. 2002a).
Ultimately, further clariﬁcation of potential gene-gene or
gene-environmental interactions can be achieved only by
well-designed large-scale prospective studies. Fifth, al-
though analysis of haplotypes is generally believed to
offer more power to detect associations than does simply
focusing on a single variant, the statistical power of hap-
lotype analysis may still be reduced by multiple hypoth-
esis testing, because of the potential large number of hap-
lotypes or haplotype combinations. Finally, it should be
noted that genetic evidence alone is not sufﬁcient to con-
ﬁrm any causal genetic variants for disease susceptibility.
If the observed relations between genotype and disease
risk can be supported by biological plausibility, the
causal arguments for the effect of CAPN10 on T2D
can be strengthened. Since little is known about the
genuine physiological functions of calpain-10 in in-
sulin secretion and action, the underlying molecular
mechanism whereby CAPN10 genetic variation inﬂu-
ences risk of T2D remains uncertain and needs further
investigation.
In conclusion, our analysis suggests that the G allele
in the CAPN10 UCSNP-43 locus may have a modest
effect on risk of T2D in a recessive model. The evidence
for the association between the risk haplotype 112/121
and T2D risk, however, is complicated by the presence
of signiﬁcant between-study heterogeneity. Inadequate
statistical power; racial/ethnic differences in frequencies
of alleles, haplotypes, and haplotype combinations;
gene-gene or gene-environment interactions; publica-
tion bias; andmultiple hypothesis testing can reasonably
contribute to the nonreplication of association in pre-
vious studies. Future large-scale, well-designed studies
using a prospective design and population-based con-
trols is needed to either reliably conﬁrm or conclusively
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Figure 3 Detecting publication bias using Begg’s funnel plot: the ORs for the individuals homozygous for the G allele versus carriers of
the C allele in the UCSNP-43 locus (A) and for carriers of the 112/121 haplotype combination versus all others (B). The funnel plot shows the
OR on a log scale by its SE, for each study included in the meta-analysis. The horizontal line indicates the pooled estimate of OR and 95%
CI, with the sloping lines representing the expected 95% CI for a given SE, under the assumption of no heterogeneity between studies.
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Figure 4 Sample size calculations for testing the effect of a susceptibility allele (or a haplotype) in a case-control study design (A) and a
family-based association study design (B). All calculations assume a recessive model, and the prevalence is 5.4% for T2D. The required sample
sizes are calculated to achieve a power of 80% for detecting various genetic effects at a one-sided type I error rate of 0.05. The frequency of
susceptibility allele in controls is shown on the X-axis. The sample size in the case-control study is the number of subjects in each group, under
the assumption of an equal number of cases and controls. The sample size in the family-based study (TDT) is the number of parents-offspring
trios.
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refute the hypothesized effect of CAPN10 on T2D. Ad-
ditional functional data are also warranted to elucidate
the potential biological role of CAPN10 in the patho-
genesis of T2D.
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Appendix
Table A1
Characteristics of Included Studies
SOURCE (STUDY
POPULATION)
SUBJECTS WITH T2D CONTROL INDIVIDUALS
No. of
Individuals
(Men/Women)
Age
(years)
Age at
Diagnosis
(years)
BMI
(kg/m2)
Plasma Fasting
Glucose
(mmol/liter)
No. of
Individuals
(Men/Women)
Age
(years)
BMI
(kg/m2)
Plasma Fasting
Glucose
(mmol/liter)
European (7 studies):
Evans et al. 2001 (British/Irish) 222 (106/116) 35–70 568 285 NA 212 (71/141) 5014 275 !5.5
Schwarz et al. 2001 (German) 291 6211 NA 254 NA 88 5112 295 NA
Schwarz et al. 2001 (Czech) 324 597 NA 305 NA 156 182 244 NA
Fingerlin et al. 2002 (Finn) 781 (438/343) 648 518 305 103 408 (168/240) 66 284 5.10.5
Malecki et al. 2002 (Polish) 229 (138/91) 5612 4611 306 NA 148 (81/67) 5714 276 NA
Orho-Melander et al. 2002 (Finn) 395 (171/224) 6110 5311 295 103 298 (140/158) 609 274 5.50.6
Rasmussen et al. 2002 (Scandinavian) 409 61 (22–86) NA 29 NA 200 52 (30–88) 25 NA
American (7 studies):
Baier et al. 2000 (Pima Indian) 298 NA NA NA NA 677 NA NA NA
Horikawa et al. 2000 (Mexican-
American) 233 NA NA NA NA 101 NA NA NA
Horikawa et al. 2000 (Finn) 192 (87/105) 619 559 295 8.92.9 192 (88/104) 619 274 5.00.5
Horikawa et al. 2000 (German) 232 (93/139) 6410 5011 285 8.44.0 88 (31/57) 5112 254 5.92.1
Hegele et al. 2001 (Canadian) 121 (47/74) NA NA NA NA 468 NA NA NA
Tsai et al. 2001 (Samoan) 172 5512 4811 NA NA 96 50 !30 !6.67
Garant et al. 2002 (African-American) 166 536 NA 316 NA 993 556 296 5.50.6
Asian (7 studies):
Ng et al. 2001 (Chinese) 103 NA NA NA NA 185 NA NA NA
Xiang et al. 2001a (Chinese) 124 (57/67) 5610 NA NA NA 144 (64/80) 5311 NA NA
Daimon et al. 2002 (Japanese) 81 (45/36) 6511 NA 264 NA 81 (46/35) 628 244 NA
Cassell et al. 2002 (Indian) 85 53 NA NA NA 323 45 NA NA
Sun et al. 2002 (Chinese) 173 NA NA NA NA 152 NA NA NA
Horikawa et al. 2003 (Japanese) 177 (114/63) 6211 5011 243 9.33.8 172 (82/90) 686 233 NA
Iwasaki et al. 2003 (Japanese) 205 NA NA NA NA 694 NA NA NA
NOTE.—Data are the meanSD or range; “NA” indicates that data were not available.
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